(Q24234934)

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Irritable bowel syndrome: Assessment of psychological disturbance and its influence on the response to fibre supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

The non-effect of pirenzepine in dietary resistant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Irritable colon and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Psyllium therapy in the irritable bowel syndrome. A double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

A Clinical Trial of Trimebutine (Mebutin) in Spastic Colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Double blind study of ispaghula in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Symptom relief with amitriptyline in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Effects of oral pinaverium bromide on colonic response to food in irritable bowel syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Dietary treatment of irritable bowel syndrome: current evidence and guidelines for future practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Fenoverine: smooth muscle synchronizer for the management of gastro-intestinal conditions. II. A trimebutine-controlled, double-blind, crossover clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Antidepressants for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Role of opioid ligands in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

How do SSRIs help patients with irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Trimebutine: Mechanism of Action, Effects on Gastrointestinal Function and Clinical Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

The effect of secoverine hydrochloride on stimulated sigmoid motility: a double-blind, placebo controlled cross-over study in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Relation of colonic transit to functional bowel disease in older people: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Bran and irritable bowel syndrome: time for reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Peppermint oil in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Zamifenacin (UK‐76, 654), a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Physicochemical and pharmacological characteristic and clinical efficacy of an anti-irritable bowel syndrome agent, polycarbophil calcium (Polyful)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: correlation of symptom relief with whole gut transit time and stool weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

A Trial of Trimebutine in Spastic Colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

A three-part controlled study of trimebutine in the treatment of irritable colon syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Wheat fibre and irritable bowel syndrome. A controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Paroxetine in Patients With Irritable Bowel Syndrome: A Pilot Open-Label Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Controlled Clinical Trial of Sedative-Anticholinergic Drugs in Patients with the Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Psyllium as therapeutic and drug delivery agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

SSRIs in IBS: sensing a dash of disappointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Antidepressants in IBS: are we deluding ourselves?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Fiber and colorectal diseases: separating fact from fiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Personality traits predict treatment outcome with an antidepressant in patients with functional gastrointestinal disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Psychotropic agents in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

The role of fiber in the treatment of irritable bowel syndrome: therapeutic recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

A randomized controlled trial of imipramine in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

The Effect of Enteric-Coated, Delayed-Release Peppermint Oil on Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Treatment of irritable bowel syndrome: a review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

The functional gastrointestinal disorders and the Rome III process

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Design of treatment trials for functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

IBS: prime problem in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Meta-analysis: The treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Towards positive diagnosis of the irritable bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Somatic comorbidities of irritable bowel syndrome: a systematic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Antidepressants for the treatment of chronic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

Evaluation of an antispasmodic agent. Methixene hydrochloride (Trest)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Effect of trimebutine on colonic myoelectrical activity in IBS patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Effects of desipramine on irritable bowel syndrome compared with atropine and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Different dietary fibre formulations and the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Bran and irritable bowel syndrome: The primary-care perspective

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Effects of a high-fiber diet on symptoms of irritable bowel syndrome: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Bran supplementation in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Mebeverine, An Effective Agent in the Irritable Colon Syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Inhibition of the colonic motor response to eating by pinaverium bromide in irritable bowel syndrome patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Measuring successful treatment of irritable bowel syndrome: is "satisfactory relief " enough?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Oral hyoscine butylbromide for irritable bowel syndrome?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Oral hyoscine butylbromide for irritable bowel syndrome?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Oral hyoscine butylbromide for irritable bowel syndrome?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Treating irritable bowel syndrome with peppermint oil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Comparison of various treatments for irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Paroxetine and irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Peppermint oil for irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021

Psyllium and the Irritable Bowel Syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003460.PUB3

7 January 2021